Acquired activated protein C resistance in sarcoma patients

Acquired activated protein C resistance (aAPCR) is seen more frequently in solid and hematological cancer patients. We aimed to investigate the presence of aAPCR and the frequency of clinically detectable thrombosis in sarcoma patients. Normalized activated protein C sensitivity ratio (nAPCSR), fact...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood coagulation & fibrinolysis 2012-07, Vol.23 (5), p.428-433
Hauptverfasser:	Soyer, Nur, Kececi, Burcin, Eroglu, Zuhal, Kamer, Serra, Ozcelik, Cagri, Cagirgan, Seckin, Tombuloglu, Murat, Sabah, Dundar, Donmez, Ayhan
Format:	Artikel
Sprache:	eng
Schlagworte:	Activated Protein C Resistance - blood Activated Protein C Resistance - complications Activated Protein C Resistance - drug therapy Activated Protein C Resistance - radiotherapy Adolescent Adult Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Biological and medical sciences Blood coagulation. Blood cells Bone Neoplasms - blood Bone Neoplasms - complications Bone Neoplasms - drug therapy Bone Neoplasms - radiotherapy Case-Control Studies Child Factor V - analysis Factor V - genetics Factor VIII - analysis Female Fundamental and applied biological sciences. Psychology Hematologic and hematopoietic diseases Humans Male Medical sciences Middle Aged Molecular and cellular biology Mutation Platelet diseases and coagulopathies Prospective Studies Sarcoma - blood Sarcoma - complications Sarcoma - drug therapy Sarcoma - radiotherapy Time Factors Venous Thromboembolism - blood Venous Thromboembolism - complications Venous Thromboembolism - drug therapy Venous Thromboembolism - radiotherapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Acquired activated protein C resistance (aAPCR) is seen more frequently in solid and hematological cancer patients. We aimed to investigate the presence of aAPCR and the frequency of clinically detectable thrombosis in sarcoma patients. Normalized activated protein C sensitivity ratio (nAPCSR), factor V Leiden (FVL) mutation, factor V (FV) levels and factor VIII (FVIII) levels were prospectively measured in 52 patients and in 52 healthy controls. Clinically detectable thrombosis was present in one patient (1.92%). Compared with healthy controls (106%), the sarcoma patients had significantly lower values of the nAPCSR at pre (87.25%) and post (94.35%) treatment period (P
ISSN:	0957-5235 1473-5733
DOI:	10.1097/MBC.0b013e3283548e19